Substudy of prospective cohort study shows link between SARS-CoV-2 infection and increased risk for postoperative venous thromboembolism
Risk for VTE Up for IBD Patients Infected With SARS-CoV-2
Odds of VTE increased 8.15-fold according to models adjusting for recent hospitalization and steroid exposure
Prophylactic Anticoagulation Aids Hospitalized COVID-19 Patients
Prophylactic-dose anticoagulation, but not treatment-dose anticoagulation, associated with lower 60-day mortality
Rare Events of ITP Associated With ChAdOx1 Vaccine
Small increased risk for idiopathic thrombocytopenic purpura seen after first dose with estimated incidence of 1.13 cases per 100,000 doses
Possible Cause Found for Rare Blood Clots Tied to Some COVID-19 Vaccines
Scientists say substandard proteins, some of which appear to split apart inside the body, can provoke the rare clots
Venous Thromboembolic Event Rates Up With ChAdOx1-S Vaccine
However, absolute risks are small, with 11 excess venous thromboembolic events per 100,000 vaccinations
Guidance Issued for Managing CVST After COVID-19 Vaccination
CVST with thrombocytopenia reported after COVID-19 vaccine with adenoviral vector; management similar to heparin-induced thrombocytopenia
12 Cases of CVST Reported for Ad26.COV2.S Vaccine in the U.S.
Time from vaccination to symptom onset varied from six to 15 days; initial presentation was headache in 11 cases
FDA Moves to Resume Use of J&J COVID Vaccine
Johnson & Johnson has agreed with the U.S. Food and Drug Administration to add a warning label to the vaccine
J&J COVID-19 Vaccine Should Be Used, but Carry Blood Clot Warning
European Medicines Agency also said the vaccine’s benefits still far outweigh its risks
- Page 1 of 2
- 1
- 2